GlassScriptPhysician profile
Peter Cole Merrill
NPI 1699099978
$7,409.50
in general payments reported to CMS, 2019-2025
33 companies · $1,290 in 2025
The $1,290 reported for 2025 was more than what 75% of Foot & Ankle Surgery providers received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $290 · 2020: $87.28 · 2021: $115 · 2022: $225 · 2023: $632 · 2024: $4,770 · 2025: $1,290.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Royalty Or License: $3,191 · Consulting Fee: $1,800 · Travel and Lodging: $928 · Food and Beverage: $773.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Royalty Or License | $3,190.62 |
| Consulting Fee | $1,800.00 |
| Travel and Lodging | $928.29 |
| Food and Beverage | $773.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fusion Orthopedics USA, LLC | $5,346.85 | 2024-2025 | Lapilock |
| Fusion Orthopedics, LLC. | $572.06 | 2023-2024 | Lapilock |
| Orthofix Medical, INC. | $183.30 | 2019-2023 | Physio-Stim |
| Smith+Nephew, INC. | $147.69 | 2019-2025 | Collagenase Santyl, Hallu Lock |
| Treace Medical Concepts, INC. | $107.82 | 2023-2025 | |
| Stryker Corporation | $94.10 | 2025 | Augment Injectable, Ortholoc 3di |
| Grt US Holding, INC. | $77.07 | 2021-2022 | |
| Abbvie INC. | $76.71 | 2021-2025 | |
| Depuy Synthes Sales INC. | $70.46 | 2019 | |
| Averitas Pharma INC. | $67.90 | 2023-2025 | Qutenza |
| Horizon Therapeutics Plc | $61.55 | 2021-2023 | Krystexxa |
| Tactile Systems Technology INC | $60.32 | 2019-2020 | |
| Melinta Therapeutics, LLC | $51.35 | 2019-2020 | |
| Biowound Solutions, INC. | $48.99 | 2025 | Bio-Connekt |
| Nevro Corp. | $48.52 | 2024 | Senza |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mimedx Group, INC. | $48.00 | 2024-2025 | |
| Paratek Pharmaceuticals, INC. | $39.08 | 2023-2024 | Nuzyra |
| Krystal Biotech INC | $30.24 | 2023 | Vyjuvek |
| Medtronic, INC. | $29.39 | 2022 | |
| Abbott Laboratories | $28.47 | 2023 | Proclaim |
| Musculoskeletal Transplant Foundation INC. | $28.31 | 2022 | |
| Merck Sharp & Dohme LLC | $27.67 | 2019 | |
| Djo, LLC | $18.89 | 2022 | |
| Organogenesis INC. | $18.46 | 2021 | |
| International Rehabilitative Sciences, INC | $16.82 | 2024 | Rs 4i Plus Sequential Stimulator |
| Integra Lifesciences Corporation | $16.06 | 2019 | |
| Globus Medical, INC. | $15.06 | 2025 | Senza |
| Misonix INC | $15.03 | 2019 | |
| Osiris Therapeutics INC. | $14.48 | 2019 | |
| Assertio Therapeutics, INC. | $13.17 | 2019 | |
| Biotissue Holdings INC. | $12.08 | 2022 | |
| Alafair Biosciences, INC. | $11.82 | 2024 | Versawrap |
| Trice Medical, INC. | $11.78 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Merrill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.